Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Imunon, Inc. (IMNN)

1.56   0.06 (4%) 01-27 16:00
Open: 1.49 Pre. Close: 1.5
High: 1.6 Low: 1.49
Volume: 106,263 Market Cap: 12(M)

Technical analysis

as of: 2023-01-27 4:45:29 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 2     One year: 2.34
Support: Support1: 1.43    Support2: 1.25
Resistance: Resistance1: 1.72    Resistance2: 2
Pivot: 1.55
Moving Average: MA(5): 1.52     MA(20): 1.54
MA(100): 1.57     MA(250): 2.68
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 32.7     %D(3): 37.1
RSI: RSI(14): 55.2
52-week: High: 7.8  Low: 1.25
Average Vol(K): 3-Month: 47 (K)  10-Days: 60 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ IMNN ] has closed below upper band by 47.2%. Bollinger Bands are 49.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.6 - 1.61 1.61 - 1.62
Low: 1.47 - 1.48 1.48 - 1.49
Close: 1.55 - 1.56 1.56 - 1.57

Company Description

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Headline News

Thu, 12 Jan 2023
2023-01-12 | NDAQ:IMNN | Press Release | Imunon Inc. - Stockhouse

Thu, 05 Jan 2023
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute's Vaccine & Immunotherapy Center to Research IMUNON's PLACCINE Vaccine Platform - Marketscreener.com

Wed, 14 Dec 2022
IMUNON Reports Inducement Grants under NASDQ Listing Rule ... - GlobeNewswire

Wed, 30 Nov 2022
IMNN: Promising Preclinical Results for PLACCINE Platform… - Yahoo Finance

Thu, 17 Nov 2022
IMUNON Announces Strategic Investment in Transomic Technologies - GlobeNewswire

Thu, 10 Nov 2022
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 0 (M)
% Held by Insiders 6.99e+006 (%)
% Held by Institutions 1.4 (%)
Shares Short 56 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.171e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -4
Return on Assets (ttm) 474.5
Return on Equity (ttm) -18.9
Qtrly Rev. Growth 500000
Gross Profit (p.s.) 0
Sales Per Share -21.4
EBITDA (p.s.) -4.6e+006
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow -22 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.08
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 65320
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.